Journal of Medical Economics
Volume 25, 2022 - Issue 1
Open access
3,066
Views
3
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States
Rebekah H. Borsea Merck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]
, Karthik Ramakrishnana Merck & Co., Inc., Kenilworth, NJ, USA
, Jyotika Gandhib CHEORS, North Wales, PA, USA
, Praveen Dhankharb CHEORS, North Wales, PA, USA
& Diana Chirovskya Merck & Co., Inc., Kenilworth, NJ, USA
Pages 954-965
|
Received 03 May 2022, Accepted 27 Jun 2022, Published online: 23 Jul 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.